Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06074380

Non Inferiority Trial Investigating Surfactants Administered Via MIST

RESEARCH DESIGN Multicenter, randomized, controlled trial. RECRUITMENT Entry criteria Preterm infants 28-35 6/7 weeks' gestation and less than 48 hours of age who have a clinical diagnosis of respiratory distress syndrome. Infants who are on NCPAP and FiO2 ≥0.30 will randomized to curosurf or infasurf via MIST.

Exclusion criteria Infants will be excluded if there is a congenital anomaly or an alternative cause for respiratory distress.

Babies who require emergent intubation will not be enrolled in the interventions.

Parental Consent will be obtained prior to randomization.

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 48 hour

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Northshore University Healthsystem

Evanston, Illinois, 60201, United States

Location status: Recruiting

Location contact

Matthew Derrick, mbbs

CONTACT

[email protected]

8475702920

About this study

INTERVENTION Infants who on CPAP who reach the threshold of 30% oxygen will be randomized to calfactant (Infasurf), 3ml/kg or poractant alfa (Curosurf), 2.5ml/kg, administered under direct laryngoscopy using a surfactant instillation catheter (MIST) 16G Angiocath (Becton Dickinson, Sandy, UT, USA).

A second dose of calfactant (Infasurf) 3ml/kg or poractant alfa (Curosurf), 1.25ml/kg, will be administered via MIST their fiO2 reaches the threshold of 30% between 6 and 48 hours after the first dose.

No further surfactant should be given in the first 7 days unless the infant reaches the intubation criteria.

POST-INTERVENTION MANAGEMENT Other than the requirement to adhere to intubation criteria in the first week, and in some cases perform a room air trial at 36 weeks corrected gestation, management will be at the discretion of the clinical team.

Titration of CPAP pressure is encouraged, with a permitted maximum of 8 cm H2O. Use of nasal IPPV is allowable for apnea, but discouraged for RDS and should only be after at least one dose of surfactant has been given. Early caffeine therapy is expected.

Criteria for intubation:

Enrolled infants on CPAP will be intubated if:

  • FiO2 ≥0.45 for 15 minutes, or if there is unremitting apnea (> 6 episodes/hour requiring intervention or in the opinion of the treating physician) or persistent respiratory acidosis (pH<7.25 and pCO2 >60) on blood gasses at least 30 minutes apart or metabolic acidosis refractory to treatment.
  • Need for an anesthetic or an intervention requiring intubation

These criteria apply during the first week of life, and to the first episode of intubation only. If the infant is intubated it is expected that another dose of surfactant will be administered.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Preterm infants 28-35 6/7 weeks' gestation and less than 48 hours of age who have a clinical diagnosis of respiratory distress syndrome confirmed by a chest x-ray on nasal continuous positive airway pressure (NCPAP) and FiO2 ≥0.30

Exclusion criteria

  • Infants will be excluded if there is a congenital anomaly or an alternative cause for respiratory distress.
  • Infants who require emergent intubation will not be enrolled in the interventions.

Treatment and study plan

MIST surfactant

Drug

Surfactant will be given via MIST while neonate is on CPAP

Primary outcomes

  1. Number of infants requiring Endotracheal Intubation

    Time frame: 7 days

    Infants will have an endotracheal placed if their inspired oxygen is >45% for more than 15 minutes

Secondary outcomes

  1. Duration of positive pressure support

    Time frame: 36 weeks corrected gestational age

    Endotracheal ventilation or Non-invasive Ventilation or CPAP or NC flow>2 L

  2. Duration of Supplemental oxygen

    Time frame: 36 weeks corrected gestational age

    Oxygen requirement to keep saturations >95%

Study contacts

Contact information is provided by the study sponsor or research team.

Matthew Derrick

CONTACT

[email protected]

18475702920

Sponsors and collaborators

Lead sponsor

Endeavor Health

Other

Registry information

Acronym: Niftisurf

Important dates

Study start
2024
Primary completion
2025
Study completion
2027
First posted
Oct 10, 2023
Registry last updated
Aug 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.